V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Boston Scientific Executive Compensation (FY25)

BSX · Marlborough, MA · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 5, 2026
463 figures on this page: 456 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Total compensation for Michael Mahoney, Chairman of the Board, President and Chief Executive Officer, came to $23,532,050 in fiscal 2025, and compared with the $21,420,801 reported for fiscal 2024, Mahoney's total was 9.9% higher. The disclosed chief executive pay ratio for fiscal 2025 is 348:1, against median employee compensation of $67,539. For fiscal 2025, shareholders backed the say-on-pay proposal with 90.6% of votes cast including abstentions in favor at the meeting held April 30, 2026. The disclosed peer group names Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Danaher Corporation, among others.
Chief executive, fiscal 2025
◇
Michael Mahoney
Median of the other named officers
$6,183,288
6 officers, excluding the chief executive
Latest say-on-pay support
=
April 30, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Mahoney: $21,420,801 → $23,532,050 (9.9% higher)
CEO pay ratio: 369:1 → 348:1 (5.7% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Boston Scientific's chief executive and what were they paid?
Total compensation for Michael Mahoney, Chairman of the Board, President and Chief Executive Officer, came to $23,532,050 in fiscal 2025. Compared with the $21,420,801 reported for fiscal 2024, Mahoney's total was 9.9% higher.
What was Boston Scientific's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 90.6% of votes cast including abstentions in favor at the meeting held April 30, 2026.
Which companies are in Boston Scientific's peer group?
The disclosed peer group names Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Danaher Corporation, among others.
What is Boston Scientific's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 348:1, against median employee compensation of $67,539.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Mahoney
Chairman of the Board President and Chief Executive Officer
◇—◇◇◇◇◇◇
Daniel Brennan
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Arthur Butcher
Executive Vice President and Group President, MedSurg and Asia Pacific
◇—◇◇◇◇◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Mahoney
Chairman of the Board President and Chief Executive Officer
◇—◇◇◇◇◇◇
Daniel Brennan
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Joseph Fitzgerald
Executive Vice President and Group President, Cardiology
◇—◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Mahoney
Chairman of the Board President and Chief Executive Officer Chairman of the Board President and Chief Executive Officer Chairman of the Board President and Chief Executive Officer
◇—◇◇◇—◇◇
Daniel Brennan
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Joseph Fitzgerald
Executive Vice President and Group President, Cardiology Executive Vice President and Group President, Cardiology Executive Vice President and Group President, Cardiology
◇—◇◇◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Mahoney
Chairman of the Board, President and Chief Executive Officer
◇—◇◇◇◇◇◇
Joseph Fitzgerald
Executive Vice President and Group President, Cardiovascular
◇—◇◇◇◇◇◇
Arthur Butcher
Executive Vice President and Group President, MedSurg and Asia Pacific
◇—◇◇◇◇◇◇
Daniel Brennan
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇◇◇◇◇
Jonathan Monson
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Jeffrey Mirviss
Former Executive Vice President and President, Peripheral Interventions
Departed during or after this year
◇—◇◇◇◇◇◇
Vance Brown
Executive Vice President, General Counsel and Corporate Secretary
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Arthur C. ButcherOptions/SARs◇——◇—◇◇
Arthur C. ButcherRSU◇——◇——◇
Arthur C. ButcherPSU◇◇◇—◇—◇
Arthur C. ButcherPSU◇◇◇—◇—◇
Daniel J. BrennanOptions/SARs◇——◇—◇◇
Daniel J. BrennanPSU◇◇◇—◇—◇
Daniel J. BrennanRSU◇——◇——◇
Daniel J. BrennanPSU◇◇◇—◇—◇
Jeffrey B. MirvissOptions/SARs◇——◇—◇◇
Jeffrey B. MirvissPSU◇◇◇—◇—◇
Jeffrey B. MirvissRSU◇——◇——◇
Jeffrey B. MirvissPSU◇◇◇—◇—◇
Jonathan R. MonsonRSU◇——◇——◇
Jonathan R. MonsonRSU◇——◇——◇
Jonathan R. MonsonOptions/SARs◇——◇—◇◇
Jonathan R. MonsonOptions/SARs◇——◇—◇◇
Joseph M. FitzgeraldPSU◇◇◇—◇—◇
Joseph M. FitzgeraldPSU◇◇◇—◇—◇
Joseph M. FitzgeraldRSU◇——◇——◇
Joseph M. FitzgeraldOptions/SARs◇——◇—◇◇
Michael F. MahoneyOptions/SARs◇——◇—◇◇
Michael F. MahoneyPSU◇——◇——◇
Michael F. MahoneyPSU◇——◇——◇
Michael F. MahoneyRSU◇——◇——◇
Vance R. BrownRSU◇——◇——◇
Vance R. BrownPSU◇◇◇—◇—◇
Vance R. BrownOptions/SARs◇——◇—◇◇
Vance R. BrownPSU◇◇◇—◇—◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Arthur ButcherRSU◇◇——
Option◇—◇2/14/2033
RSU◇◇——
Option◇—◇2/13/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇5/2/2032
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇2/16/2032
Option◇—◇2/12/2034
Vance BrownRSU◇◇——
Option◇—◇2/12/2034
RSU◇◇——
RSU◇◇——
Option◇—◇2/14/2033
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/16/2032
Option◇—◇2/13/2035
Daniel BrennanRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Joseph FitzgeraldOption◇—◇2/13/2035
Option◇—◇2/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/16/2032
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇7/1/2030
RSU◇◇——
Option◇—◇2/12/2034
Jeffrey MirvissPSU◇◇——
PSU◇◇——
Option◇—◇2/13/2035
RSU◇◇——
Option◇—◇2/16/2032
RSU◇◇——
RSU◇◇——
Option◇—◇2/14/2033
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2034
PSU◇◇——
PSU◇◇——
Jonathan MonsonRSU◇◇——
Option◇—◇2/12/2034
Option◇—◇12/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/13/2035
Option◇—◇2/16/2032
RSU◇◇——
Option◇—◇2/14/2033
Option◇—◇7/1/2035
Michael MahoneyRSU◇◇——
Option◇—◇2/16/2032
Option◇—◇2/12/2034
RSU◇◇——
Option◇—◇2/13/2035
RSU◇◇——
Option◇—◇2/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Edward J. Ludwig
Lead independent director
◇◇————◇
David S. Wichmann
◇◇————◇
Ellen M. Zane
◇◇————◇
Susan E. Morano
◇◇————◇
Jessica L. Mega
◇◇————◇
David C. Habiger
◇◇————◇
Cheryl Pegus
◇◇————◇
Charles J. Dockendorff
◇—————◇
Christophe P. Weber, Michael F. Mahoney and Cathy R. Smith served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Equity is delivered as Restricted Stock.
Stock ownership guideline: 5x annual cash retainer ($625,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Agilent Technologies, Inc. A
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Danaher Corporation DHR
  • Edwards Lifesciences Corporation EW
  • GE HealthCare Technologies Inc. GEHC
  • Hologic, Inc. HOLX
  • Intuitive Surgical, Inc. ISRG
  • Medtronic plc MDT
  • Quest Diagnostics Incorporated DGX
  • Stryker Corporation SYK
  • Thermo Fisher Scientific Inc. TMO
  • Zimmer Biomet Holdings Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 30, 2026=◇◇◇
2024May 1, 2025=◇◇◇
2023May 2, 2024=◇◇◇
2022May 4, 2023=◇◇◇
2021May 3, 2022=◇◇◇
2020May 6, 2021=◇◇◇
2019May 7, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Boston Scientific files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Boston Scientific disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Boston Scientific sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Boston Scientific's disclosed peer group is defensible, who names Boston Scientific back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
463 figures on this page: 456 cited to the filing that reported them, 7 calculated from figures it prints.
456 cited to the filing
7 calculated from the filing

Documents cited

  1. 0000885725-26-000036
  2. 0000885725-26-000025
    CEO Pay Ratio · Director Compensation · Director Compensation Table · Grants of Plan-Based Awards · and 3 more sections
  3. 0000885725-25-000028
  4. 0000885725-25-000017
    Summary Compensation Table
  5. 0000885725-24-000048
  6. 0000885725-24-000033
    Summary Compensation Table
  7. 0000885725-23-000028
  8. 0000885725-23-000017
    Summary Compensation Table
  9. 0001104659-22-057017
  10. 0000885725-21-000016
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000885725-20-000024
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Boston Scientific executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BSX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Boston Scientific and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Boston Scientific discloses

The companies named in BSX's own disclosed peer group.

Abbott LaboratoriesAgilent Technologies, Inc.Baxter International Inc.Becton, Dickinson and CompanyEdwards Lifesciences CorporationGE HealthCare Technologies Inc.Hologic, Inc.Intuitive Surgical, Inc.Medtronic plcStryker CorporationZimmer Biomet Holdings Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy